司美格鲁肽对超重及肥胖2型糖尿病患者的临床疗效及安全性分析  

Clinical Efficacy and Safety Analysis of Semaglutide in Overweight and Obese Patients with Type 2 Diabetes

作　　者：刘飞燕 陈丹 赵磊 LIU Feiyan;CHEN Dan;ZHAO Lei(Department of Endocrinology,Yizheng Hospital,Nanjing Gulou Hospital Group,Yizheng,Jiangsu Province,211400 China)

机构地区：[1]南京鼓楼医院集团仪征医院内分泌科,江苏仪征211400

出　　处：《糖尿病新世界》2023年第18期88-91,共4页Diabetes New World Magazine

摘　　要：目的探讨对超重及肥胖2型糖尿病者予司美格鲁肽治疗的疗效及安全性。方法选取2022年1—12月南京鼓楼医院集团仪征医院收治的超重及肥胖2型糖尿病者84例,按照随机数字表法分为两组,各42例。对照组采用二甲双胍治疗,观察组采用二甲双胍联合司美格鲁肽治疗,对比两组治疗效果。结果治疗后,两组血糖指标均下降,且观察组比对照组更低,差异有统计学意义(P<0.05)。治疗后,两组胰岛素敏感指数降低,胰岛素抵抗指数升高,且观察组均更优,差异有统计学意义(P<0.05)。治疗后,两组总胆固醇、三酰甘油均下降,且观察组比对照组更低,差异有统计学意义(P<0.05)。结论对超重及肥胖2型糖尿病者予司美格鲁肽治疗疗效确切,可改善血糖水平与胰岛素抵抗状态,能降低血脂水平,安全性高。Objective To investigate the efficacy and safety of semaglutide in overweight and obese patients with type 2 diabetes.Methods 84 overweight and obese type 2 diabetes patients admitted to Yizheng Hospital of Nanjing Gulou Hospital Group from January to December 2022 were seleceted,and divided them into two groups according to random number table,42 cases in each group.The control group was treated with metformin,while the observation group was treated with metformin combined with smectide.The therapeutic effects of the two groups were compared.Results After treatment,blood glucose indicators in both groups decreased,and the observation group was lower than the control group,the difference was statistically significant(P<0.05).After treatment,the insulin sensitivity index decreased and the insulin resistance index increased in both groups,and the observation group was better,the difference was statistically significant(P<0.05).After treatment,total cholesterol and triglycerides in both groups decreased,and the observation group was lower than the control group,the difference was statistically significant(P<0.05).Conclusion Smaglutide is effective in the treatment of overweight and obese patients with type 2 diabetes.It can improve blood glucose level and insulin resistance,reduce blood lipid level,and has high safety.

关 键 词：司美格鲁肽 二甲双胍 2型糖尿病 超重 肥胖 不良反应 

分 类 号：R4[医药卫生—临床医学]